70% of breast tumors containing germline mutations in BRCA1 fall in the category of triple-negative breast cancer (TNBC), a highly aggressive, highly metastatic subtype, comprising approximately 15% of all breast cancer cases, characterized by the absence of hormone receptors with no amplification of growth signal receptor (6). This evidence concerns the gene BRCA1 and breast carcinoma.